Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

SESN 4-DAY DEADLINE ALERT: Hagens Berman Alerts Sesen Bio (SESN) Investors to OCT. 18TH LEAD PLAINTIFF DEADLINE in Securities Class Action, Encourages Investors with Significant Losses to Contact Firm's Attorneys Now

10/14/2021 | 10:07am EST

SAN FRANCISCO, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Sesen Bio, Inc. (NASDAQ: SESN) investors with losses in excess of $250,000 to submit your losses now.

Class Period: Dec. 21, 2020 – Aug. 17, 2021
Lead Plaintiff Deadline: Oct. 18, 2021
Visit: www.hbsslaw.com/investor-fraud/SESN
Contact An Attorney Now: SESN@hbsslaw.com
                                                844-916-0895

Sesen Bio, Inc. (SESN) Securities Fraud Class Action:

The complaint alleges that Defendants misrepresented clinical trial data for Sesen’s lead product candidate Vicineum for the treatment of certain non-muscle invasive bladder cancer.

Specifically, Defendants concealed that: (1) the company’s clinical trial for Vicineum had more than 2,000 protocol violations, including 215 classified as “major,” (2) three of the company’s clinical investigators were found guilty of “serious noncompliance,” including backdating data, (3) the company submitted tainted data for Vicineum to the FDA, (4) the company’s clinical trials showed that Vicineum leaked out into the body and caused serious side effects and increased risks for fatal liver injury.

The truth began to emerge on Aug. 13, 2021, when Sesen announced the FDA did not approve the BLA in its present form and sought additional clinical/statistical data.

Then, on Aug. 16, 2021, the company revealed it needed to conduct an additional clinical trial to provide the FDA with additional efficacy and safety data.

Finally, on Aug. 18, 2021, STAT published an article entitled “Sesen Bio trial of cancer drug marked by misconduct and worrisome side effects, documents show.” STAT cited hundreds of pages of internal documents and three people familiar with the matter reported the Vicineum clinical trial “was marked by thousands of violations of study rules, damning investigator conduct, and worrying signs of toxicity the company did not publicly disclose.”

These events sent the price of Sesen shares sharply lower.

“We’re focused on investors’ losses and proving Sesen lied to them about the prospects for Vicineum,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you invested in Sesen and have significant losses, or have knowledge that may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding Sesen should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email SESN@hbsslaw.com.

About Hagens Berman
Hagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:
Reed Kathrein, 844-916-0895


Latest news "Companies"
12:50pAIR MAURITIUS : Suspension of passenger commercial flights from South Africa - 27 Nov. 2021
PU
12:40pRIT TECHNOLOGIES : Jeff Safovich, chief technology officer at RiT Tech, on why the grass can be greener on the other side of COP26 for the data centre sector
PU
12:38pHYZN DEADLINE : Kessler Topaz Meltzer & Check, LLP Reminds Investors of Hyzon Motors Inc. of Deadline in Securities Fraud Class Action Lawsuit
BU
12:37pSensormatic Solutions- Shopper Traffic Data In U.S. Indicates That Visits To Physical Stores On Black Friday Remain Down -28.3% Compared To 2019
RE
12:34pSensormatic solutions - shopper traffic data in u.s. indicates that visits to physical stores on black friday remain down -28.3% compared to 2019
RE
12:31pPROMPERÚ Invites You to Participate in the 2nd Tourism Investment Forum
BU
12:26pBEST BLACK FRIDAY & CYBER MONDAY VITAMIX DEALS (2021) : E310, 7500, V1200, 5200, A3500 & More Deals Summarized by Deal Stripe
BU
12:23pSensormatic Solutions by Johnson Controls Shopper Traffic Analytics Reveal In-Store Black Friday Shopping Increased Year-Over-Year
BU
12:11pBLACK FRIDAY & CYBER MONDAY TEMPUR-PEDIC DEALS (2021) : Best Mattress, Pillow & More Tempur-Pedic Sales Published by Retail Egg
BU
12:01pHYZN FINAL DEADLINE NOTICE : ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages Hyzon Motors Inc. f/k/a Decarbonization Plus Acquisition Corporation Investors with Losses to Secure Counsel Before Important November 29 Deadline in Securities Class Action – HYZN, HYZNW, DCRB, DCRBW, DCRBU
GL
Latest news "Companies"